Capula Management’s Nektar Therapeutics NKTR Stock Holding History

Capula Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,443	Closed	-$82K	–	635
2022 Q2	$82K	Buy	+1,443	New	+$91K	﹤0.01%	299

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capula Management's NKTR Position: Q3 2022 in Review

Capula Management sold out of Nektar Therapeutics (NKTR) in Q3 2022, closing a stake of 1,443 shares — an estimated $82K sold.

Capula Management first reported a position in NKTR in Q2 2022 and held it in 1 quarter. The position peaked at $82K in Q2 2022. 230 funds tracked by Wall St. Rank hold NKTR as of Q3 2022.

Capula Management reported no remaining Nektar Therapeutics position as of Q3 2022 after selling out during the quarter.
Capula Management sold 1,443 Nektar Therapeutics shares in Q3 2022, an estimated $82K.
Capula Management first reported a position in Nektar Therapeutics in Q2 2022 and held it in 1 quarter.
Capula Management's Nektar Therapeutics position peaked at $82K in Q2 2022.
230 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2022.

Based on Capula Management's 13F filing for Q3 2022, filed 14 Nov 2022.